These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
337 related articles for article (PubMed ID: 30875177)
1. Common elements in opioid use disorder guidelines for buprenorphine prescribing. Atkinson TJ; Pisansky AJB; Miller KL; Yong RJ Am J Manag Care; 2019 Mar; 25(3):e88-e97. PubMed ID: 30875177 [TBL] [Abstract][Full Text] [Related]
2. Patient Barriers and Facilitators to Medications for Opioid Use Disorder in Primary Care. Tofighi B; Williams AR; Chemi C; Suhail-Sindhu S; Dickson V; Lee JD Subst Use Misuse; 2019; 54(14):2409-2419. PubMed ID: 31429351 [No Abstract] [Full Text] [Related]
3. Training in office-based opioid treatment with buprenorphine in US residency programs: A national survey of residency program directors. Tesema L; Marshall J; Hathaway R; Pham C; Clarke C; Bergeron G; Yeh J; Soliman M; McCormick D Subst Abus; 2018; 39(4):434-440. PubMed ID: 29513136 [TBL] [Abstract][Full Text] [Related]
4. Buprenorphine prescribing for opioid use disorder in medical practices: can office-based out-patient care address the opiate crisis in the United States? Rhee TG; Rosenheck RA Addiction; 2019 Nov; 114(11):1992-1999. PubMed ID: 31307111 [TBL] [Abstract][Full Text] [Related]
5. Group-based treatment of opioid use disorder with buprenorphine: A systematic review. Sokol R; LaVertu AE; Morrill D; Albanese C; Schuman-Olivier Z J Subst Abuse Treat; 2018 Jan; 84():78-87. PubMed ID: 29195596 [TBL] [Abstract][Full Text] [Related]
6. Prevalence and treatment of opioid use disorders among primary care patients in six health systems. Lapham G; Boudreau DM; Johnson EA; Bobb JF; Matthews AG; McCormack J; Liu D; Samet JH; Saxon AJ; Campbell CI; Glass JE; Rossom RC; Murphy MT; Binswanger IA; Yarborough BJH; Bradley KA; Drug Alcohol Depend; 2020 Feb; 207():107732. PubMed ID: 31835068 [TBL] [Abstract][Full Text] [Related]
7. Very early disengagement and subsequent re-engagement in primary care Office Based Opioid Treatment (OBOT) with buprenorphine. Hui D; Weinstein ZM; Cheng DM; Quinn E; Kim H; Labelle C; Samet JH J Subst Abuse Treat; 2017 Aug; 79():12-19. PubMed ID: 28673522 [TBL] [Abstract][Full Text] [Related]
8. Primary care and medication management characteristics among patients receiving office-based opioid treatment with buprenorphine. Du CX; Shi J; Tetrault JM; Madden LM; Barry DT Fam Pract; 2022 Mar; 39(2):234-240. PubMed ID: 34893825 [TBL] [Abstract][Full Text] [Related]
9. Staff Attitudes toward Buprenorphine before and after Implementation of an Office-Based Opioid Treatment Program in an Urban Teaching Clinic. James JR; Marolf M; Klein JW; Blalock KL; Merrill JO; Tsui JI Subst Use Misuse; 2021; 56(11):1569-1575. PubMed ID: 34282999 [TBL] [Abstract][Full Text] [Related]
11. Psychoactive medications and disengagement from office based opioid treatment (obot) with buprenorphine. Weinstein ZM; Cheng DM; Quinn E; Hui D; Kim H; Gryczynski G; Samet JH Drug Alcohol Depend; 2017 Jan; 170():9-16. PubMed ID: 27865152 [TBL] [Abstract][Full Text] [Related]
12. Network Analysis of Medical Claims Data Suggests Network-Based, Regional Targeting and Intervention Delivery Strategies to Increase Access to Office Based Opioid Treatment (OBOT) for Opioid Use Disorder (OUD). Green HD; Kaminski PC Inquiry; 2024; 61():469580241238422. PubMed ID: 38528788 [TBL] [Abstract][Full Text] [Related]
13. The case for a medication first approach to the treatment of opioid use disorder. Winograd RP; Presnall N; Stringfellow E; Wood C; Horn P; Duello A; Green L; Rudder T Am J Drug Alcohol Abuse; 2019; 45(4):333-340. PubMed ID: 31084515 [No Abstract] [Full Text] [Related]
14. Three-year Retention Rates With Office-based Treatment of Buprenorphine for Opioid Use Disorder in a Private Family Medicine Practice. Cope K; DeMicco J; Salib J; Michael M; Yakoub P; Daoud K; Cope R J Addict Med; 2022 Nov-Dec 01; 16(6):716-721. PubMed ID: 35913992 [TBL] [Abstract][Full Text] [Related]
15. Office-Based Opioid Treatment with Buprenorphine (OBOT-B): Statewide Implementation of the Massachusetts Collaborative Care Model in Community Health Centers. LaBelle CT; Han SC; Bergeron A; Samet JH J Subst Abuse Treat; 2016 Jan; 60():6-13. PubMed ID: 26233698 [TBL] [Abstract][Full Text] [Related]
16. Outcomes of a novel office-based opioid treatment program in an internal medicine resident continuity practice. Pytell JD; Buresh ME; Graddy R Addict Sci Clin Pract; 2019 Dec; 14(1):46. PubMed ID: 31856915 [TBL] [Abstract][Full Text] [Related]
17. Association of a Multimodal Educational Intervention for Primary Care Physicians With Prescriptions of Buprenorphine for Opioid Use Disorders. Clark B; Kai M; Dix R; White J; Rozenfeld Y; Levy S; Engstrom K JAMA Netw Open; 2019 Oct; 2(10):e1913818. PubMed ID: 31642929 [TBL] [Abstract][Full Text] [Related]
18. A Financial Model for Team-Based Opioid Use Disorder Treatment. Farrar M; White Z; Hulkower S; Fagan EB; Wilson CG J Am Board Fam Med; 2020; 33(1):124-128. PubMed ID: 31907253 [TBL] [Abstract][Full Text] [Related]
19. Patient Perceptions of Integrating Meditation-based Interventions in Office-based Opioid Treatment with Buprenorphine: A Mixed-methods Survey. Tofighi B; Marini C; Lee JD; Garland EL J Addict Med; 2023 Sep-Oct 01; 17(5):517-520. PubMed ID: 37788602 [TBL] [Abstract][Full Text] [Related]
20. Integration of Buprenorphine Treatment with Primary Care: Comparative Effectiveness on Retention, Utilization, and Cost. Hsu YJ; Marsteller JA; Kachur SG; Fingerhood MI Popul Health Manag; 2019 Aug; 22(4):292-299. PubMed ID: 30543495 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]